The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its ...

Cancer drug specialist Exelixis (NASDAQ: EXEL) was quite the stock market star on Friday. Following news that it's making a ...

Exelixis, Inc. (NASDAQ:EXEL) authorized repurchasing up to an additional $500 million of the company’s common stock before ...

NTT DATA, a global digital business and IT services leader, today announced the international launch of its next-generation Smart AI Agenttm. This advanced AI tool is a cornerstone of the company's ...

A high omega-3, low omega-6 diet with fish oil led to a significant reduction in a biomarker for prostate cancer progression ...

The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...

Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...

Gastric Neuroendocrine Tumors market Forecast. DelveInsight's Gastric Neuroendocrine Tumors Market report offers an in-depth understanding of the epidemiol ...

Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...